| 1 | Role of the liver in the sustained normalisation of A1c over 2 years following short‐term insulin therapy in early type 2 diabetes | 4.5 | 2 | Citations (PDF) |
| 2 | Understanding Patient Registries for Diabetes: A Scoping Review of Published Literature | 1.1 | 1 | Citations (PDF) |
| 3 | Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity | 6.2 | 80 | Citations (PDF) |
| 4 | Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials | 2.5 | 2 | Citations (PDF) |
| 5 | Can a Combined Epigenetic-Biomarker Score Supplant Chronologic Age as an Independent Determinant of Incident Death in Adults With Dysglycemia | 1.8 | 1 | Citations (PDF) |
| 6 | Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial | 2.9 | 2 | Citations (PDF) |
| 7 | Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk | 6.2 | 9 | Citations (PDF) |
| 8 | Contemporary Clinical Perspectives on Targeting Remission of Type 2 Diabetes | 4.0 | 15 | Citations (PDF) |
| 9 | Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial | 4.5 | 3 | Citations (PDF) |
| 10 | Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the
ORIGIN
trial | 4.5 | 1 | Citations (PDF) |
| 11 | Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study | 2.2 | 13 | Citations (PDF) |
| 12 | Non-coronary peripheral arterial complications in people with type 2 diabetes: a Swedish retrospective cohort study | 6.9 | 8 | Citations (PDF) |
| 13 | Visit-to-visit variability in multiple biological measurements and cognitive performance and risk of cardiovascular disease: A cohort study | 1.0 | 4 | Citations (PDF) |
| 14 | Determinants of serious health
outcome‐free
status in
middle‐aged
and older people with dysglycaemia: Exploratory analysis of the
ORIGIN
trial | 4.5 | 0 | Citations (PDF) |
| 15 | Development and first‐stage validation of a digital version of the Digit Symbol Substitution test for use in assessing cognitive function in older people with diabetes | 4.5 | 2 | Citations (PDF) |
| 16 | Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis | 18.0 | 133 | Citations (PDF) |
| 17 | Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes | 9.4 | 1 | Citations (PDF) |
| 18 | Do nonglycaemic effects such as weight loss account for
HbA1c
lowering with efpeglenatide?: Insights from the
AMPLITUDE‐
O trial | 4.5 | 1 | Citations (PDF) |
| 19 | A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity | 6.2 | 12 | Citations (PDF) |
| 20 | Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial | 9.4 | 2 | Citations (PDF) |
| 21 | Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches | 2.0 | 0 | Citations (PDF) |
| 22 | Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The
ELIXA
trial | 4.5 | 3 | Citations (PDF) |
| 23 | Nailfold capillaroscopy and deep learning in diabetes | 2.9 | 24 | Citations (PDF) |
| 24 | Thyroid Dysfunction and Cardiovascular Events in Patients With Dysglycemia | 1.8 | 5 | Citations (PDF) |
| 25 | Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial | 0.8 | 11 | Citations (PDF) |
| 26 | Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial | 18.0 | 26 | Citations (PDF) |
| 27 | Identifying blood biomarkers for type 2 diabetes subtyping: a report from the ORIGIN trial | 7.5 | 10 | Citations (PDF) |
| 28 | Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis | 6.2 | 11 | Citations (PDF) |
| 29 | General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial | 9.4 | 25 | Citations (PDF) |
| 30 | A culturally tailored personaliseD nutrition intErvention in South ASIan women at risk of Gestational Diabetes Mellitus (DESI-GDM): a randomised controlled trial protocol | 1.9 | 7 | Citations (PDF) |
| 31 | Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study | 18.0 | 113 | Citations (PDF) |
| 32 | Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus | 3.6 | 15 | Citations (PDF) |
| 33 | Association of Intima‐Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta‐Analysis of 20 Prospective Studies | 4.0 | 13 | Citations (PDF) |
| 34 | Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis | 6.2 | 37 | Citations (PDF) |
| 35 | GDF15 promotes weight loss by enhancing energy expenditure in muscle | 37.9 | 246 | Citations (PDF) |
| 36 | Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus: Reply | 3.6 | 3 | Citations (PDF) |
| 37 | Diet, cardiovascular disease, and mortality in 80 countries | 2.2 | 151 | Citations (PDF) |
| 38 | Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes | 13.7 | 22 | Citations (PDF) |
| 39 | Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial | 4.5 | 24 | Citations (PDF) |
| 40 | High BMI and the risk for incident type 1 Diabetes Mellitus: a systematic review and meta-analysis of aggregated cohort studies | 9.4 | 18 | Citations (PDF) |
| 41 | Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia | 5.8 | 2 | Citations (PDF) |
| 42 | Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia - Experiences from the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial | 2.2 | 0 | Citations (PDF) |
| 43 | Consensus report: Definition and interpretation of remission in type 2 diabetes | 2.9 | 23 | Citations (PDF) |
| 44 | Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes | 4.0 | 77 | Citations (PDF) |
| 45 | Myopia and Early-Onset Type 2 Diabetes: A Nationwide Cohort Study | 4.0 | 12 | Citations (PDF) |
| 46 | Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial | 6.2 | 23 | Citations (PDF) |
| 47 | Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial | 18.0 | 126 | Citations (PDF) |
| 48 | Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the
REWIND
randomized trial | 4.5 | 15 | Citations (PDF) |
| 49 | Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial | 3.0 | 32 | Citations (PDF) |
| 50 | Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes | 6.2 | 71 | Citations (PDF) |
| 51 | HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial | 6.2 | 8 | Citations (PDF) |
| 52 | Identification of genetic effects underlying type 2 diabetes in South Asian and European populations | 4.4 | 61 | Citations (PDF) |
| 53 | Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes | 4.0 | 14 | Citations (PDF) |
| 54 | Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study | 2.0 | 33 | Citations (PDF) |
| 55 | Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial | 4.0 | 4 | Citations (PDF) |
| 56 | Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia: Data from the ORIGIN Trial | 2.6 | 1 | Citations (PDF) |
| 57 | Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation | 25.2 | 700 | Citations (PDF) |
| 58 | Efficacy and safety outcomes of dulaglutide by baseline
HbA1c
: A post hoc analysis of the
REWIND
trial | 4.5 | 7 | Citations (PDF) |
| 59 | Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation | 2.6 | 3 | Citations (PDF) |
| 60 | Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684–691 | 6.2 | 1 | Citations (PDF) |
| 61 | Obesity in late adolescence and incident type 1 diabetes in young adulthood | 7.5 | 48 | Citations (PDF) |
| 62 | Glucose Intolerance in Pregnancy and Offspring Obesity in Late Adolescence | 6.2 | 40 | Citations (PDF) |
| 63 | Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to
iGlarLixi
in the
LixiLan ONE CAN
randomized trial | 4.5 | 4 | Citations (PDF) |
| 64 | Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines täglichen vs. wöchentlichen Titrationsalgorithmus für den Wechsel von Basalinsulin zur Fixkombination iGlarLixi bei Typ-2-Diabetespatienten in Kanada | 0.2 | 0 | Citations (PDF) |
| 65 | Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial” | 18.0 | 0 | Citations (PDF) |
| 66 | Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study | 6.2 | 8 | Citations (PDF) |
| 67 | Cushing Syndrome Secondary to Ectopic ACTH Production in Pregnancy: A Case Report 2022, 1, | | 0 | Citations (PDF) |
| 68 | A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes | 9.4 | 12 | Citations (PDF) |
| 69 | Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial | 7.3 | 40 | Citations (PDF) |
| 70 | Are U‐shaped relationships between risk factors and outcomes artifactual? | 2.9 | 2 | Citations (PDF) |
| 71 | Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers | 2.0 | 0 | Citations (PDF) |
| 72 | Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin | 2.2 | 24 | Citations (PDF) |
| 73 | Effect of Diabetes Health Coaching on Glycemic Control and Quality of Life in Adults Living With Type 2 Diabetes: A Community-Based, Randomized, Controlled Trial | 1.8 | 28 | Citations (PDF) |
| 74 | Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial | 6.2 | 58 | Citations (PDF) |
| 75 | Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents | 6.2 | 18 | Citations (PDF) |
| 76 | Design and baseline characteristics of the
AMPLITUDE‐O
cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist | 4.5 | 21 | Citations (PDF) |
| 77 | Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study | 4.0 | 19 | Citations (PDF) |
| 78 | Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood | 4.0 | 26 | Citations (PDF) |
| 79 | Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents | 4.0 | 8 | Citations (PDF) |
| 80 | The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke | 4.0 | 16 | Citations (PDF) |
| 81 | Creating Composite Indices From Continuous Variables for Research: The Geometric Mean | 6.2 | 11 | Citations (PDF) |
| 82 | Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial | 4.0 | 23 | Citations (PDF) |
| 83 | Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial | 2.7 | 8 | Citations (PDF) |
| 84 | Insulin Therapy: The Discovery That Shaped a Century | 1.8 | 19 | Citations (PDF) |
| 85 | Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity | 6.6 | 53 | Citations (PDF) |
| 86 | Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries | 10.6 | 134 | Citations (PDF) |
| 87 | Short‐term intensive insulin as induction and maintenance therapy for the preservation of beta‐cell function in early type 2 diabetes (
RESET‐IT Main
): A 2‐year randomized controlled trial | 4.5 | 20 | Citations (PDF) |
| 88 | Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood | 4.0 | 14 | Citations (PDF) |
| 89 | Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents | 4.0 | 4 | Citations (PDF) |
| 90 | NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia – A brief report from the ORIGIN trial | 2.4 | 4 | Citations (PDF) |
| 91 | Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes | 6.2 | 404 | Citations (PDF) |
| 92 | Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial | 21.7 | 50 | Citations (PDF) |
| 93 | Economic Analysis of a Diabetes Health Coaching Intervention for Adults Living With Type 2 Diabetes: A Single-Centre Evaluation From a Community-Based Randomized Controlled Trial | 1.8 | 5 | Citations (PDF) |
| 94 | Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND | 9.4 | 56 | Citations (PDF) |
| 95 | Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials | 4.0 | 125 | Citations (PDF) |
| 96 | Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | 34.5 | 753 | Citations (PDF) |
| 97 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials | 21.7 | 1,413 | Citations (PDF) |
| 98 | Adolescent cognitive function and incident early-onset type 2 diabetes | 8.2 | 12 | Citations (PDF) |
| 99 | HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression | 6.2 | 136 | Citations (PDF) |
| 100 | Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters | 6.2 | 9 | Citations (PDF) |
| 101 | Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial | 7.5 | 69 | Citations (PDF) |
| 102 | Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors | 1.8 | 1 | Citations (PDF) |
| 103 | Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood | 6.2 | 30 | Citations (PDF) |
| 104 | Novel Biomarkers for Change in Renal Function in People With Dysglycemia | 6.2 | 12 | Citations (PDF) |
| 105 | The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial | 21.7 | 115 | Citations (PDF) |
| 106 | Are large simple trials for dementia prevention possible? | 1.8 | 21 | Citations (PDF) |
| 107 | Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study | 6.2 | 67 | Citations (PDF) |
| 108 | Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial | 9.4 | 5 | Citations (PDF) |
| 109 | Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis | 9.4 | 31 | Citations (PDF) |
| 110 | The obesity paradigm in cardiovascular disease: the need for differentiated weight management | 2.2 | 2 | Citations (PDF) |
| 111 | Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial | 2.2 | 81 | Citations (PDF) |
| 112 | Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial | 17.9 | 262 | Citations (PDF) |
| 113 | Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk | 18.0 | 425 | Citations (PDF) |
| 114 | Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin | 4.0 | 31 | Citations (PDF) |
| 115 | PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid | 4.2 | 38 | Citations (PDF) |
| 116 | Hyperglycaemia, Ejection Fraction and the Risk of Heart Failure or Cardiovascular Death in Patients with Type 2 Diabetes and a Recent Acute Coronary Syndrome | 7.3 | 20 | Citations (PDF) |
| 117 | Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial | 6.2 | 27 | Citations (PDF) |
| 118 | Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals | 4.0 | 82 | Citations (PDF) |
| 119 | Influence of Genetic Ancestry on Human Serum Proteome | 6.5 | 33 | Citations (PDF) |
| 120 | Identification of Circulating Proteins Associated With Blood Pressure Using Mendelian Randomization | 2.9 | 16 | Citations (PDF) |
| 121 | Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus | 18.0 | 106 | Citations (PDF) |
| 122 | Adolescent Obesity and Early-Onset Type 2 Diabetes | 6.2 | 150 | Citations (PDF) |
| 123 | ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study | 6.2 | 33 | Citations (PDF) |
| 124 | OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind | 0.3 | 0 | Citations (PDF) |
| 125 | MON-636 The Relationship Between Glucose Control & Cognitive Function in People with Diabetes After a Lacunar Stroke | 0.3 | 0 | Citations (PDF) |
| 126 | Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis | 2.2 | 0 | Citations (PDF) |
| 127 | Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk | 6.2 | 14 | Citations (PDF) |
| 128 | Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States | 4.5 | 44 | Citations (PDF) |
| 129 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial | 62.1 | 2,775 | Citations (PDF) |
| 130 | Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial | 62.1 | 565 | Citations (PDF) |
| 131 | Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk | 7.4 | 23 | Citations (PDF) |
| 132 | Dysglycemia and the Density of the Coronary Vasa Vasorum | 6.2 | 23 | Citations (PDF) |
| 133 | Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss | 17.1 | 282 | Citations (PDF) |
| 134 | Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial | 2.0 | 14 | Citations (PDF) |
| 135 | Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial | 6.2 | 30 | Citations (PDF) |
| 136 | A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease | 1.1 | 19 | Citations (PDF) |
| 137 | The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes | 1.8 | 14 | Citations (PDF) |
| 138 | Blood HER2 and Uromodulin as Causal Mediators of CKD | 0.4 | 30 | Citations (PDF) |
| 139 | Do sulphonylureas still have a place in clinical practice? | 21.7 | 100 | Citations (PDF) |
| 140 | The Genetic Link Between Diabetes and Atherosclerosis | 2.6 | 22 | Citations (PDF) |
| 141 | Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks | 11.1 | 614 | Citations (PDF) |
| 142 | Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization | 18.0 | 38 | Citations (PDF) |
| 143 | Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL) | 2.9 | 27 | Citations (PDF) |
| 144 | Insulin resistance and cardiovascular outcomes in the
ORIGIN
trial | 4.5 | 11 | Citations (PDF) |
| 145 | Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD | 6.2 | 20 | Citations (PDF) |
| 146 | Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes | 3.5 | 5 | Citations (PDF) |
| 147 | Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood | 9.4 | 56 | Citations (PDF) |
| 148 | Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial | 6.2 | 41 | Citations (PDF) |
| 149 | P6345Effect of free testosterone levels on cardiovascular outcomes: a Mendelian randomization analysis | 2.2 | 0 | Citations (PDF) |
| 150 | Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community‐based survey in China | 4.8 | 13 | Citations (PDF) |
| 151 | Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study | 21.7 | 38 | Citations (PDF) |
| 152 | Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease | 2.3 | 88 | Citations (PDF) |
| 153 | Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study | 21.7 | 177 | Citations (PDF) |
| 154 | Design and baseline characteristics of participants in the
R
esearching cardiovascular
E
vents with a
W
eekly
IN
cretin in
D
iabetes (
REWIND
) trial on the cardiovascular effects of dulaglutide | 4.5 | 176 | Citations (PDF) |
| 155 | Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201 | 6.2 | 2 | Citations (PDF) |
| 156 | The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial | 2.7 | 3 | Citations (PDF) |
| 157 | Systematic review: Can non-mydriatic cameras accurately detect diabetic retinopathy? | 5.8 | 15 | Citations (PDF) |
| 158 | Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial | 4.0 | 48 | Citations (PDF) |
| 159 | The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study | 4.0 | 11 | Citations (PDF) |
| 160 | Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study | 3.4 | 5 | Citations (PDF) |
| 161 | Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus | 4.0 | 99 | Citations (PDF) |
| 162 | Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials | 21.7 | 496 | Citations (PDF) |
| 163 | Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes | 11.1 | 167 | Citations (PDF) |
| 164 | Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus | 18.0 | 18 | Citations (PDF) |
| 165 | Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study | 2.0 | 25 | Citations (PDF) |
| 166 | Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial | 21.7 | 292 | Citations (PDF) |
| 167 | Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial | 5.8 | 0 | Citations (PDF) |
| 168 | Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study | 1.5 | 37 | Citations (PDF) |
| 169 | Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution | 6.5 | 123 | Citations (PDF) |
| 170 | Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans | 3.4 | 24 | Citations (PDF) |
| 171 | Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People | 4.0 | 15 | Citations (PDF) |
| 172 | Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response | 2.3 | 3 | Citations (PDF) |
| 173 | Cardiometabolic Health in Adults Born Premature With Extremely Low Birth Weight | 4.5 | 106 | Citations (PDF) |
| 174 | Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial | 6.2 | 57 | Citations (PDF) |
| 175 | Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study | 3.4 | 72 | Citations (PDF) |
| 176 | Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology | 3.4 | 7 | Citations (PDF) |
| 177 | BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents | 6.2 | 80 | Citations (PDF) |
| 178 | Self-Perceived Emotional Distress and Diabetes Risk Among Young Men | 3.2 | 5 | Citations (PDF) |
| 179 | Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study | 6.2 | 176 | Citations (PDF) |
| 180 | ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial | 7.5 | 111 | Citations (PDF) |
| 181 | Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke | 0.6 | 2 | Citations (PDF) |
| 182 | Drugs in diabetes in 2016, changes in endocrinology in 2015. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke | 0.6 | 1 | Citations (PDF) |
| 183 | Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067–1074 | 6.2 | 14 | Citations (PDF) |
| 184 | Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo | 2.9 | 95 | Citations (PDF) |
| 185 | Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies | 4.0 | 8 | Citations (PDF) |
| 186 | Cognitive Performance at Late Adolescence and the Risk for Impaired Fasting Glucose Among Young Adults | 4.0 | 22 | Citations (PDF) |
| 187 | Association Between Shortened Leukocyte Telomere Length and Cardiometabolic Outcomes | 3.8 | 322 | Citations (PDF) |
| 188 | Risk Prediction for Early CKD in Type 2 Diabetes | 4.2 | 123 | Citations (PDF) |
| 189 | Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease | 2.2 | 120 | Citations (PDF) |
| 190 | Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes | 2.9 | 29 | Citations (PDF) |
| 191 | Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort | 6.2 | 128 | Citations (PDF) |
| 192 | Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity | 3.8 | 152 | Citations (PDF) |
| 193 | Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals | 2.9 | 64 | Citations (PDF) |
| 194 | Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats | 3.2 | 22 | Citations (PDF) |
| 195 | Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population | 5.2 | 40 | Citations (PDF) |
| 196 | Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia | 18.0 | 69 | Citations (PDF) |
| 197 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | 34.5 | 2,260 | Citations (PDF) |
| 198 | Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus | 5.3 | 113 | Citations (PDF) |
| 199 | What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts | 3.0 | 35 | Citations (PDF) |
| 200 | Sleep quality and risk of diabetes and coronary artery disease among young men | 2.2 | 21 | Citations (PDF) |
| 201 | Sensitization of T lymphocytes to thyroid antigen in autoimmune thyroid disease as demonstrated by the monocyte procoagulant activity test | 2.8 | 2 | Citations (PDF) |
| 202 | Evaluating the Feasibility and Impact of an Internet-Based Lifestyle Management Program in a Diabetes Care Setting | 4.6 | 12 | Citations (PDF) |
| 203 | The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial | 6.2 | 76 | Citations (PDF) |
| 204 | Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366 | 6.2 | 0 | Citations (PDF) |
| 205 | Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366 | 6.2 | 1 | Citations (PDF) |
| 206 | Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub‐study of the DREAM trial | 2.9 | 40 | Citations (PDF) |
| 207 | Willingness to take drugs to prevent serious chronic diseases (自愿服用药物以预防严重的慢性疾病) | 2.9 | 3 | Citations (PDF) |
| 208 | White blood cell subtypes, insulin resistance and β‐cell dysfunction in high‐risk individuals – the PROMISE cohort | 2.3 | 46 | Citations (PDF) |
| 209 | Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels | 10.6 | 173 | Citations (PDF) |
| 210 | Cognitive Function and the Risk for Diabetes Among Young Men | 6.2 | 68 | Citations (PDF) |
| 211 | Association of cyclooxygenase-2 genetic variant with cardiovascular disease | 2.2 | 49 | Citations (PDF) |
| 212 | Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial | 6.2 | 239 | Citations (PDF) |
| 213 | Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial | 7.5 | 48 | Citations (PDF) |
| 214 | Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial | 6.2 | 18 | Citations (PDF) |
| 215 | Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations? | 7.5 | 34 | Citations (PDF) |
| 216 | Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial | 62.1 | 146 | Citations (PDF) |
| 217 | Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial | 7.5 | 12 | Citations (PDF) |
| 218 | The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia | 6.2 | 80 | Citations (PDF) |
| 219 | Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study | 6.2 | 24 | Citations (PDF) |
| 220 | Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial | 6.2 | 118 | Citations (PDF) |
| 221 | Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial | 1.7 | 9 | Citations (PDF) |
| 222 | Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults | 6.2 | 113 | Citations (PDF) |
| 223 | Cost implications of the use of basal insulin glargine in people with early dysglycemia: The ORIGIN trial | 2.4 | 13 | Citations (PDF) |
| 224 | Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial | 2.9 | 55 | Citations (PDF) |
| 225 | Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored | 21.7 | 286 | Citations (PDF) |
| 226 | Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial | 2.2 | 95 | Citations (PDF) |
| 227 | Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial | 21.7 | 57 | Citations (PDF) |
| 228 | Prospective association of 25(OH)D with metabolic syndrome | 2.3 | 47 | Citations (PDF) |
| 229 | Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study | 2.1 | 28 | Citations (PDF) |
| 230 | Can community retail pharmacist and diabetes expert support facilitate insulin initiation by family physicians? Results of the AIM@GP randomized controlled trial | 2.5 | 16 | Citations (PDF) |
| 231 | Setting the record straight on TIDE: a lost opportunity for patients with diabetes | 7.5 | 2 | Citations (PDF) |
| 232 | Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population | 6.2 | 22 | Citations (PDF) |
| 233 | Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice | 1.5 | 31 | Citations (PDF) |
| 234 | Dysglycaemia, vasculopenia, and the chronic consequences of diabetes | 21.7 | 52 | Citations (PDF) |
| 235 | Increased cardiovascular risk after pre‐eclampsia in women with dysglycaemia | 2.9 | 15 | Citations (PDF) |
| 236 | Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial | 6.2 | 54 | Citations (PDF) |
| 237 | Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction | 2.2 | 5 | Citations (PDF) |
| 238 | Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial | 12.4 | 125 | Citations (PDF) |
| 239 | Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial | 2.2 | 230 | Citations (PDF) |
| 240 | Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922 | 6.2 | 1 | Citations (PDF) |
| 241 | Short Leg Length, a Marker of Early Childhood Deprivation, Is Associated With Metabolic Disorders Underlying Type 2 Diabetes | 6.2 | 31 | Citations (PDF) |
| 242 | Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events | 6.2 | 42 | Citations (PDF) |
| 243 | Postnatal Metabolic and Reproductive Consequences of Fetal and Neonatal Exposure to the Smoking Cessation Drug Bupropion | 2.1 | 11 | Citations (PDF) |
| 244 | Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial | 6.2 | 101 | Citations (PDF) |
| 245 | Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes | 2.1 | 78 | Citations (PDF) |
| 246 | Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population | 2.3 | 60 | Citations (PDF) |
| 247 | Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI | 7.5 | 11 | Citations (PDF) |
| 248 | Cardiovascular Risk in Patients with Early Renal Insufficiency | 2.5 | 10 | Citations (PDF) |
| 249 | Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes | 6.2 | 326 | Citations (PDF) |
| 250 | Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes | 6.2 | 31 | Citations (PDF) |
| 251 | Glycemic Index Predicts Individual Glucose Responses after Self-Selected Breakfasts in Free-Living, Abdominally Obese Adults | 2.9 | 16 | Citations (PDF) |
| 252 | Maternal antioxidants prevent β‐cell apoptosis and promote formation of dual hormone‐expressing endocrine cells in male offspring following fetal and neonatal nicotine exposure | 2.9 | 18 | Citations (PDF) |
| 253 | Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit | 6.2 | 17 | Citations (PDF) |
| 254 | Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients | 5.3 | 61 | Citations (PDF) |
| 255 | n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia | 34.5 | 889 | Citations (PDF) |
| 256 | Impact of a computerized system for evidence-based diabetes care on completeness of records: a before–after study | 3.1 | 9 | Citations (PDF) |
| 257 | Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids | 2.6 | 94 | Citations (PDF) |
| 258 | Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study | 2.0 | 100 | Citations (PDF) |
| 259 | Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia | 34.5 | 1,540 | Citations (PDF) |
| 260 | Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study | 0.7 | 13 | Citations (PDF) |
| 261 | Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study | 3.0 | 37 | Citations (PDF) |
| 262 | The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression | 7.8 | 123 | Citations (PDF) |
| 263 | Association of 25(OH)D and PTH with Metabolic Syndrome and Its Traditional and Nontraditional Components | 4.0 | 110 | Citations (PDF) |
| 264 | Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes | 34.5 | 968 | Citations (PDF) |
| 265 | Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth | 2.9 | 4 | Citations (PDF) |
| 266 | Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population | 2.9 | 6 | Citations (PDF) |
| 267 | Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy | 17.9 | 534 | Citations (PDF) |
| 268 | Establishing a relationship between prolactin and altered fatty acid β-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells | 2.9 | 72 | Citations (PDF) |
| 269 | Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada | 2.1 | 52 | Citations (PDF) |
| 270 | Computerized clinical decision support systems for chronic disease management: A decision-maker-researcher partnership systematic review | 12.1 | 199 | Citations (PDF) |
| 271 | Shared Electronic Vascular Risk Decision Support in Primary Care | 8.1 | 45 | Citations (PDF) |
| 272 | Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score | 2.2 | 252 | Citations (PDF) |
| 273 | Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community | 6.2 | 14 | Citations (PDF) |
| 274 | Serious Cardiovascular Outcomes in Diabetes | 18.0 | 98 | Citations (PDF) |
| 275 | Prospective Associations of Vitamin D With β-Cell Function and Glycemia | 4.2 | 132 | Citations (PDF) |
| 276 | Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial | 7.5 | 59 | Citations (PDF) |
| 277 | Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE) | 2.3 | 153 | Citations (PDF) |
| 278 | Low-Dose Combination Therapy With Rosiglitazone And Metformin to Prevent Type 2 Diabetes Mellitus (CANOE Trial): A Double-Blind Randomized Controlled Study | 0.5 | 1 | Citations (PDF) |
| 279 | Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes | 2.2 | 55 | Citations (PDF) |
| 280 | Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes | 7.5 | 36 | Citations (PDF) |
| 281 | Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study | 7.5 | 54 | Citations (PDF) |
| 282 | Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis | 2.5 | 7 | Citations (PDF) |
| 283 | Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis | 1.4 | 208 | Citations (PDF) |
| 284 | Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate? | 1.9 | 148 | Citations (PDF) |
| 285 | Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes | 2.9 | 40 | Citations (PDF) |
| 286 | Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial | 2.9 | 15 | Citations (PDF) |
| 287 | Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance | 6.2 | 176 | Citations (PDF) |
| 288 | Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial | 6.2 | 497 | Citations (PDF) |
| 289 | Response to Letter Regarding Article, “Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction” | 18.0 | 0 | Citations (PDF) |
| 290 | A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs | 6.2 | 146 | Citations (PDF) |
| 291 | Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease | 18.0 | 99 | Citations (PDF) |
| 292 | Macular Edema and Thiazolidinediones—Reply | 2.2 | 0 | Citations (PDF) |
| 293 | Long-Term Consequences of Fetal and Neonatal Nicotine Exposure: A Critical Review | 3.8 | 340 | Citations (PDF) |
| 294 | Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose | 6.2 | 54 | Citations (PDF) |
| 295 | Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study | 6.2 | 35 | Citations (PDF) |
| 296 | Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus | 34.5 | 3,448 | Citations (PDF) |
| 297 | Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes | 6.2 | 322 | Citations (PDF) |
| 298 | The Effect of Oral Antidiabetic Agents on A1C Levels | 6.2 | 304 | Citations (PDF) |
| 299 | Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes | 34.5 | 1,245 | Citations (PDF) |
| 300 | The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study | 0.1 | 381 | Citations (PDF) |
| 301 | Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus | 34.5 | 2,719 | Citations (PDF) |
| 302 | Metabolic Syndrome and Risk of Acute Myocardial Infarction | 2.3 | 217 | Citations (PDF) |
| 303 | Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study | 62.1 | 231 | Citations (PDF) |
| 304 | Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada | 2.6 | 91 | Citations (PDF) |
| 305 | Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes | 7.5 | 52 | Citations (PDF) |
| 306 | Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors | 6.2 | 430 | Citations (PDF) |
| 307 | Is it possible to reduce cardiovascular risk with glucose-lowering approaches? | 31.8 | 10 | Citations (PDF) |
| 308 | Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial | 1.2 | 190 | Citations (PDF) |
| 309 | Association of Hematological Parameters with Insulin Resistance and β-Cell Dysfunction in Nondiabetic Subjects | 4.0 | 79 | Citations (PDF) |
| 310 | Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction | 18.0 | 128 | Citations (PDF) |
| 311 | Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program | 6.2 | 70 | Citations (PDF) |
| 312 | Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine | 2.5 | 34 | Citations (PDF) |
| 313 | Intensive glucose control and macrovascular outcomes in type 2 diabetes | 7.5 | 1,113 | Citations (PDF) |
| 314 | Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme | 5.8 | 27 | Citations (PDF) |
| 315 | Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction | 2.9 | 31 | Citations (PDF) |
| 316 | Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose | 2.3 | 57 | Citations (PDF) |
| 317 | Albuminuria in chronic heart failure: prevalence and prognostic importance | 62.1 | 284 | Citations (PDF) |
| 318 | a meta-analysis of the effect of oral antidiabetic agents on A1c levels at 12 weeks | 1.8 | 0 | Citations (PDF) |
| 319 | Rosiglitazone prevents diabetes by increasing beta‐cell mass in an animal model of type 2 diabetes characterized by reduced beta‐cell mass at birth | 4.5 | 23 | Citations (PDF) |
| 320 | Maternal nicotine exposure increases oxidative stress in the offspring | 3.7 | 88 | Citations (PDF) |
| 321 | Effects of Intensive Glucose Lowering in Type 2 Diabetes | 34.5 | 7,577 | Citations (PDF) |
| 322 | Relationship of epicardial fat thickness and fasting glucose | 2.2 | 101 | Citations (PDF) |
| 323 | Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) | 2.9 | 176 | Citations (PDF) |
| 324 | Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics | 2.9 | 19 | Citations (PDF) |
| 325 | Assessing the Willingness of Young and Healthy People to take Preventive Medication for Chronic Diseases. | 1.8 | 0 | Citations (PDF) |
| 326 | Dysglycemia and a History of Reproductive Risk Factors | 6.2 | 24 | Citations (PDF) |
| 327 | Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points | 2.7 | 8 | Citations (PDF) |
| 328 | The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure | 8.1 | 207 | Citations (PDF) |
| 329 | Increased Pancreatic Beta-Cell Apoptosis following Fetal and Neonatal Exposure to Nicotine Is Mediated via the Mitochondria | 3.8 | 70 | Citations (PDF) |
| 330 | Fetal and Neonatal Nicotine Exposure in Wistar Rats Causes Progressive Pancreatic Mitochondrial Damage and Beta Cell Dysfunction | 2.3 | 74 | Citations (PDF) |
| 331 | Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus | 18.0 | 660 | Citations (PDF) |
| 332 | Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study | 5.8 | 55 | Citations (PDF) |
| 333 | Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia | 5.8 | 38 | Citations (PDF) |
| 334 | Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies | 5.8 | 529 | Citations (PDF) |
| 335 | Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk | 18.0 | 190 | Citations (PDF) |
| 336 | The effects of exercise training on insulin resistance in patients with coronary artery disease | 2.2 | 9 | Citations (PDF) |
| 337 | Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review | 2.3 | 91 | Citations (PDF) |
| 338 | Low Socioeconomic Status and Increased Risk of Severe Hypoglycemia in Type 1 Diabetes: A Systematic Literature Review | 1.8 | 9 | Citations (PDF) |
| 339 | Dysglycemia in a community sample of people treated for schizophrenia: The Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study | 2.3 | 35 | Citations (PDF) |
| 340 | A Family-based Intervention to Promote Healthy Lifestyles in an Aboriginal Community in Canada | 1.7 | 80 | Citations (PDF) |
| 341 | Transgenerational effects of fetal and neonatal exposure to nicotine | 1.4 | 55 | Citations (PDF) |
| 342 | Effect of Ramipril on the Incidence of Diabetes | 34.5 | 706 | Citations (PDF) |
| 343 | Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | 62.1 | 1,611 | Citations (PDF) |
| 344 | Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial | 4.5 | 31 | Citations (PDF) |
| 345 | A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study | 2.9 | 194 | Citations (PDF) |
| 346 | Reply to comment on: Gerstein HC, Pogue J, Mann JFE et al. (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48:1749–1755 | 7.5 | 1 | Citations (PDF) |
| 347 | Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study | 1.4 | 28 | Citations (PDF) |
| 348 | Why don't pigs get diabetes? Explanations for variations in diabetes susceptibility in human populations living in a diabetogenic environment | 1.2 | 55 | Citations (PDF) |
| 349 | Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?Cmaj, 2006, 174, 1090-1091 | 1.2 | 2 | Citations (PDF) |
| 350 | Diabetes susceptibilityCmaj, 2006, 174, 1598-1598 | 1.2 | 0 | Citations (PDF) |
| 351 | Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study | 18.0 | 243 | Citations (PDF) |
| 352 | Fetal and neonatal exposure to nicotine in Wistar rats results in increased beta cell apoptosis at birth and postnatal endocrine and metabolic changes associated with type 2 diabetes | 7.5 | 126 | Citations (PDF) |
| 353 | Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies | 7.5 | 943 | Citations (PDF) |
| 354 | The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis | 7.5 | 241 | Citations (PDF) |
| 355 | The Burden of Treatment Failure in Type 2 Diabetes: Response to Brown et al. | 6.2 | 4 | Citations (PDF) |
| 356 | Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure | 18.0 | 216 | Citations (PDF) |
| 357 | Insulin Therapy in People Who Have Dysglycemia and Type 2 Diabetes Mellitus: Can It Offer Both Cardiovascular Protection and Beta-Cell Preservation? | 3.5 | 21 | Citations (PDF) |
| 358 | The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences | 1.2 | 57 | Citations (PDF) |
| 359 | Glycemia and Risk for Cardiovascular Disease | 9.6 | 0 | Citations (PDF) |
| 360 | Authors’ Response: Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3′-Triiodothyronine | 4.0 | 1 | Citations (PDF) |
| 361 | The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes | 6.2 | 80 | Citations (PDF) |
| 362 | Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial | 2.9 | 10 | Citations (PDF) |
| 363 | Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study | 5.3 | 110 | Citations (PDF) |
| 364 | Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial | 7.5 | 160 | Citations (PDF) |
| 365 | A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer | 4.0 | 418 | Citations (PDF) |
| 366 | Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study | 1.4 | 83 | Citations (PDF) |
| 367 | Acarbose in the treatment of elderly patients with type 2 diabetes | 5.8 | 105 | Citations (PDF) |
| 368 | Development of Renal Disease in People at High Cardiovascular Risk | 0.4 | 137 | Citations (PDF) |
| 369 | Does a Combination Regimen of Thyroxine (T4) and 3,5,3′-Triiodothyronine Improve Depressive Symptoms Better Than T4Alone in Patients with Hypothyroidism? Results of a Double-Blind, Randomized, Controlled Trial | 4.0 | 174 | Citations (PDF) |
| 370 | Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease | 18.0 | 269 | Citations (PDF) |
| 371 | A disturbed glucose metabolic state (dysglycaemia) is a key risk factor for cardiovascular events | 0.1 | 2 | Citations (PDF) |
| 372 | Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies | 0.1 | 26 | Citations (PDF) |
| 373 | Dysglycemia: A Key Cardiovascular Risk Factor | 3.2 | 17 | Citations (PDF) |
| 374 | Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors | 3.5 | 9 | Citations (PDF) |
| 375 | The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial | 5.8 | 157 | Citations (PDF) |
| 376 | Cardiovascular Outcomes and Renal Disease | 9.6 | 5 | Citations (PDF) |
| 377 | Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE | 4.8 | 76 | Citations (PDF) |
| 378 | The value of large, robust trials: the HOPE study | 0.3 | 1 | Citations (PDF) |
| 379 | Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP) | 62.1 | 264 | Citations (PDF) |
| 380 | Fußgeschwüre bei Diabetes | 1.6 | 0 | Citations (PDF) |
| 381 | Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial | 9.6 | 1,273 | Citations (PDF) |
| 382 | Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals | 16.5 | 2,204 | Citations (PDF) |
| 383 | Perceived exertion with glucose ingestion in adolescent males with IDDM | 0.8 | 30 | Citations (PDF) |
| 384 | Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview | 62.1 | 2,079 | Citations (PDF) |
| 385 | Miglitol, an α-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes | 2.6 | 20 | Citations (PDF) |
| 386 | Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) | 62.1 | 905 | Citations (PDF) |
| 387 | A controlled evaluation of a national continuing medical education programme designed to improve family physicians' implementation of diabetes-specific clinical practice guidelines | 2.9 | 31 | Citations (PDF) |
| 388 | Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors | 3.1 | 19 | Citations (PDF) |
| 389 | Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent | 1.8 | 45 | Citations (PDF) |
| 390 | Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study | 2.3 | 94 | Citations (PDF) |
| 391 | Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent | 1.8 | 6 | Citations (PDF) |
| 392 | Ramipril slowed the decline in renal function among patients with nephropathy and proteinuria not due to insulin-dependent diabetes mellitus | 0.4 | 0 | Citations (PDF) |
| 393 | The Association of Microalbuminuria and Mortality in Non—Insulin-Dependent Diabetes Mellitus | 8.1 | 582 | Citations (PDF) |
| 394 | Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease | 0.4 | 15 | Citations (PDF) |
| 395 | Risk factors for acute myocardial infarction in Indians: a case-control study | 62.1 | 262 | Citations (PDF) |
| 396 | Dysglycaemia and risk of cardiovascular disease | 62.1 | 170 | Citations (PDF) |
| 397 | A New Mutation in the Thyroid Hormone Receptor (TR) β Gene (V458A) in a Family with Resistance to Thyroid Hormone (RTH) | 4.4 | 12 | Citations (PDF) |
| 398 | Does treatment withl-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? | 2.4 | 212 | Citations (PDF) |
| 399 | Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study | 6.2 | 69 | Citations (PDF) |
| 400 | Users' Guides to the Medical Literature | 16.5 | 122 | Citations (PDF) |
| 401 | Users' Guides to the Medical Literature | 16.5 | 717 | Citations (PDF) |
| 402 | Users' Guides to the Medical Literature | 16.5 | 846 | Citations (PDF) |
| 403 | Users' Guides to the Medical Literature | 16.5 | 626 | Citations (PDF) |
| 404 | Spectrum of quality of life impairment in hypothyroidism | 2.1 | 70 | Citations (PDF) |
| 405 | Users' Guides to the Medical Literature | 16.5 | 584 | Citations (PDF) |
| 406 | Users' Guides to the Medical Literature | 16.5 | 1,903 | Citations (PDF) |
| 407 | Incidence of Postpartum Thyroid Dysfunction in Patients with Type I Diabetes Mellitus | 9.6 | 156 | Citations (PDF) |
| 408 | How Common Is Postpartum Thyroiditis? | 8.1 | 105 | Citations (PDF) |
| 409 | Separate Induction of MHC and Thyroid Microsomal Antigen (McAg) Expression on Thyroid Cell Monolayers: Enhancement of Lectin-Induced McAg Expression by Interferon-γ* | 4.0 | 11 | Citations (PDF) |
| 410 | IMMUNOMODULATORY EFFECT OF THE TREATMENT OF GRAVES’DISEASE ON ANTIGEN-SPECIFIC MONOCYTE PROCOAGULANT ACTIVITY PRODUCTION | 2.3 | 2 | Citations (PDF) |
| 411 | Thyrocyte HLA-DR Expression and Interferon-γProduction in Autoimmune Thyroid Disease* | 4.0 | 115 | Citations (PDF) |
| 412 | Effects of lifelong testosterone exposure on health and disease using Mendelian randomization | 0.7 | 47 | Citations (PDF) |
| 413 | The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes | 6.2 | 6 | Citations (PDF) |
| 414 | Type 2 Diabetes Remission: A Systematic Review and Meta-analysis of Nonsurgical Randomized Controlled Trials | 6.2 | 7 | Citations (PDF) |
| 415 | Relationship between sarcopenia and type 2 diabetes mellitus among adults with prediabetes: evidence from a prospective cohort study | 3.4 | 3 | Citations (PDF) |
| 416 | Mendelian randomization study implicates inflammaging biomarkers in retinal vasculature, cardiovascular diseases, and longevity | 10.9 | 5 | Citations (PDF) |
| 417 | Dementia Risk in People With Type 1 Diabetes and Associated Risk Factors: A Nationwide, Register-Based Cohort Study | 6.2 | 5 | Citations (PDF) |
| 418 | Global trends and age-period-cohort analysis for the disability adjusted life years and mortality of type 2 diabetes mellitus due to diet high in sugar-sweetened beverages | 3.3 | 1 | Citations (PDF) |
| 419 | Normal-Range Gestational Glucose Challenge Test and Incident Type 2 Diabetes: A Population-Based Cohort Study | 6.2 | 0 | Citations (PDF) |
| 420 | Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes | 4.5 | 0 | Citations (PDF) |
| 421 | Incretin Mimetics in Cancer and Cardiovascular Disease | 4.6 | 1 | Citations (PDF) |
| 422 | Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Prevention | 1.3 | 3 | Citations (PDF) |
| 423 | Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis | 0.5 | 0 | Citations (PDF) |
| 424 | A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline | 4.5 | 0 | Citations (PDF) |
| 425 | Cardiovascular Risk Reduction With GLP-1 RA Drugs | 18.0 | 0 | Citations (PDF) |
| 426 | Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: A descriptive compatibility analysis | 2.9 | 0 | Citations (PDF) |
